Company
Gilead Sciences Inc
NASDAQ:GILD
Gilead Sciences Inc is a biopharmaceutical company. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. Gilead Sciences Inc offers products in HIV, Onocolgy, Liver Disease, Vekulaery and Other.
86 stories · page 1 of 5
Maxcyte: At the forefront of cell therapy revolution; exits 2020 in rude health
"With a resilient business model we have every reason to remain highly optimistic for the future"
Gilead says remdesivir drug unaffected by new strains of coronavirus
Remdesivir does not target the spike proteins of the coronavirus that are altered in new variants of the coronavirus
WHO advises against use of Gilead’s remdesivir for COVID-19 treatment
The agency said there is currently no evidence that it improves survival or the need for ventilation
Gilead Sciences says remdesivir plays important role for COVID-19 patients treatment
The drug made US$873mln sales in the third quarter, helping group revenues to rise to US$6.6bn
Gilead Sciences slams WHO after trial shows remdesivir not effective in avoiding COVID-19 death
The Solidarity study proved that the candidate had little to no effect in helping patients’ chances of survival
Anger as US snaps up supplies of Gilead coronavirus treatment Remdesivir
Developed economies have to go through the US pharma giant, which holds the patent.
Gilead slaps multi-thousand-dollar price tag on coronavirus treatment remdesivir
The pharma giant intends to charge developed countries US$2,340 for a five-day treatment, while other parts of the world can access generic versions